Information Provided By:
Fly News Breaks for January 27, 2020
Jan 27, 2020 | 07:52 EDT
Cowen analyst Yaron Werber lowered his price target on BeiGene after the company disclosed its pamiparib global Phase 3 trial was converted to Phase 2 due to poor enrollment as the study lacks the chemo maintenance arm. The analyst said there are many upcoming data catalysts that should maintain interest in the stock. Werber maintained his Outperform rating on BeiGene shares.